Who
Richard L. Lindstrom
Director
Company insider
Files Form 4 as: Director, Ocular Therapeutix; Director, Lensar; Director, Harrow; Director, TearLab; Director, Vertical Health Solutions; Director, Tlc Vision.
In numbers
- Trades disclosed
- 93
- Buys
- 5
- Sells
- 6
- Bought
- $1.4M
- Sold
- $976K
- Companies
- 6
- Companies where not an officer
- 6
- First trade
- 30 Dec 2005
- Last trade
- 10 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jun 2026filed 12 Jun 2026 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Code A | —14,000 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | OCUL Ocular Therapeutixoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,000 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | OCUL Ocular Therapeutixoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,000 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Code A | —14,000 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | LNSR LensarMedical Devices | SEC FORM 4 Code A | —17,421 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | LNSR LensarMedical Devices | SEC FORM 4 Code A | —17,421 at $0.00 | filing |
| 20 Feb 2026filed 24 Feb 2026 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Bought | $461K60,229 at $7.66 | filing |
| 20 Feb 2026filed 24 Feb 2026 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Bought | $461K60,229 at $7.66 | filing |
| 11 Jun 2025filed 13 Jun 2025 | OCUL Ocular Therapeutixoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,000 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Code A | —14,000 at $0.00 | filing |
| 23 May 2025filed 28 May 2025 | LNSR LensarMedical Devices | SEC FORM 4 Code A | —7,374 at $0.00 | filing |
| 8 May 2025filed 12 May 2025 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Bought | $70K10,000 at $6.96 | filing |
| 24 Jul 2024filed 26 Jul 2024 | OCUL Ocular Therapeutixoption or derivative · Biotechnology | SEC FORM 4 Code A | —36,000 at $0.00 | filing |
| 24 Jul 2024filed 26 Jul 2024 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 7 May 2024filed 9 May 2024 | LNSR LensarMedical Devices | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 27 Feb 2024filed 26 Jul 2024 | OCUL Ocular Therapeutixoption or derivative · Biotechnology | SEC FORM 4 Code M | —18,939 at $0.00 | filing |
| 27 Feb 2024filed 26 Jul 2024 | OCUL Ocular Therapeutixoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,363 at $0.00 | filing |
| 27 Feb 2024filed 26 Jul 2024 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Code M | $167K18,939 at $8.80 | filing |
| 27 Feb 2024filed 26 Jul 2024 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Code M | $100K11,363 at $8.80 | filing |
| 14 Jun 2023filed 16 Jun 2023 | OCUL Ocular Therapeutixoption or derivative · Biotechnology | SEC FORM 4 Code A | —36,000 at $0.00 | filing |
News
Ocular Therapeutix (NASDAQ:OCUL) Stock: Insider Todd Anderman Sells 11,984 SharesOCUL · themarketsdaily.com · 15 Oct 2026Ocular Therapeutix (NASDAQ:OCUL) Upgraded to Strong-Buy at UBS GroupOCUL · dailypolitical.com · 14 Oct 2026Contrasting Ocular Therapeutix (NASDAQ:OCUL) and Bausch Health Cos (NYSE:BHC)OCUL · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name Richard L. Lindstrom; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.